Ugandan Firm Dei BioPharma Files Seven US Patents for mRNA Cancer Vaccines Targeting Recurrence

A Ugandan biotechnology firm, Dei BioPharma (搜索)搜索该词条, has filed seven patent applications in the United States outlining a modular portfolio of messenger RNA (mRNA) cancer-vaccine technologies, with the long-term goal of preventing cancer recurrence. The applications, lodged with the US Patent and Trademark Office (USPTO) between August 18 and 25, position the firm as a locally anchored programme within the global effort to develop off-the-shelf cancer immunotherapies.

The initiative is spearheaded by Dr. Matthias Magoola, founder of Dei BioPharma (搜索)搜索该词条 and lead inventor on the filings. According to the firm, the seven-application portfolio establishes a molecularly organized framework for pre-manufactured, HLA-matched mRNA vaccine candidates, speaking directly to its long-term objective of building a platform broad enough to address major cancer-causing molecular events across many patient subgroups.

A Molecular, Not Organ-Based, Approach

The programme is built around a central biological insight articulated in the firm's August 26 statement: "cancer is not one disease, and no single vaccine can credibly treat or prevent every cancer." As a scalable alternative, Dei BioPharma (搜索)搜索该词条 proposes a governed library of pre-manufactured vaccine candidates directed to recurrent molecular events that occur across defined groups of patients.

Under this model, a patient would be matched by the tumor's molecular alteration and, where relevant, by human leukocyte antigen (HLA) type, rather than by organ of origin alone. This differs from traditional cancer classification, which often focuses on the location of the tumor, such as breast or lung cancer. Instead, the proposed vaccines target specific molecular abnormalities within the tumor regardless of its origin, enabling a more personalized approach.

"The filings span recurrent fusion junctions, driver mutations, tumor-specific frameshifts, viral oncoproteins and an omnibus architecture designed to support multiple target-defined products," the statement reads.

The Seven Patent Targets

The seven applications cover a range of tumor targets. These include a BCR-ABL (搜索)搜索该靶点 fusion-junction target associated with fusion-positive leukaemia—an abnormal fusion gene that causes certain blood cancers, most notably chronic myeloid leukemia (搜索)搜索该疾病 (CML)—as well as an EGFRvIII (搜索)搜索该靶点 deletion-junction target relevant to certain glioma (搜索)搜索该疾病 subgroups.

Additional filings cover an NPM1 (搜索)搜索该靶点 target in molecularly defined acute myeloid leukaemia (搜索)搜索该疾病, a multiplex RAS (搜索)搜索该靶点-hotspot design aimed at RAS-mutant tumors across several organs, a TP53 (搜索)搜索该靶点 R175H target, and sequence-attenuated HPV16/18 (搜索)搜索该靶点 cassettes addressing HPV-driven malignancies. The seventh application describes the omnibus platform architecture intended to support multiple target-specific products.

Dr. Magoola described the innovation as an approach in which pre-manufactured vaccine candidates are directed at molecular changes that recur across defined groups of patients. "Our ambition is global and deliberately long-term: to develop a modular immune platform capable of addressing the molecular drivers behind an expanding share of human cancers," he said. "These filings are an effort to build, target by target, the scientific and manufacturing foundation that will make many cancers preventable and controllable or less likely to return."

From COVID-19 mRNA to Cancer

The technology leverages mRNA, a method made familiar by COVID-19 vaccines. However, adapting mRNA technology for cancer presents unique challenges, as the immune system must learn to differentiate abnormal tumor cells from the patient's own healthy tissues. The researchers emphasize that these patent filings represent a scientific endeavor and are not yet available treatments for patients. Extensive research, laboratory work, and clinical trials will be necessary before these potential vaccines can be considered for regulatory approval.

Dei BioPharma (搜索)搜索该词条 said it plans to prioritize candidates based on how common a target is, biological validation, unmet medical need, manufacturability, and a feasible clinical pathway, with particular interest in settings such as minimal residual disease and recurrence prevention.

A Growing African Biotech Footprint

This is not Dr. Magoola's first innovation. He previously co-authored peer-reviewed work proposing a strict filter for candidate targets: that a target recur within a defined subgroup, be absent from essential normal tissue, and be naturally presented by tumor cells. The Ugandan scientist holds more than 100 patents filed with the USPTO, with about 70 published to date.

Established in 2014 by Dr. Magoola, Dei BioPharma (搜索)搜索该词条 operates a manufacturing complex at Matugga in Wakiso District near Kampala, described as one of the largest such facilities on the African continent and inaugurated in 2021. Licensed by Uganda's National Drug Authority in 2024 to manufacture a wide range of medicines, the firm aims to produce vaccines, biologics, biosimilars, and mRNA-based therapeutics for African and global markets.

In prior filings over the last two years, the USPTO has accepted applications for a universal mRNA cancer-vaccine platform and a lower-cost immune therapy, and in July the US Food and Drug Administration provided preliminary comments on PSI-033, a proposed biosimilar to the cancer drug Yervoy查看药品详情. Dr. Magoola noted that this is the first time an African-based entity has taken the lead in such a groundbreaking initiative, underscoring Uganda's growing role in biotechnological innovation.